The board of directors of PuraPharm Corporation Limited announced that Mr. Lau Ka Kuen has been appointed as the Chief Financial Officer of the Company with effect from 24 September 2018. Meanwhile, Ms. Li Wai Shan has been re-designated from Chief Financial and Operating Officer of the Company to General Manager of the Group's clinic segment with effect from 24 September 2018. Mr. Lau will be responsible for the Group's overall financial reporting and management, corporate finance and investment activities, investor relations and company secretarial matters.

Ms. Li will be responsible for the overall operation and development of the Group's clinic segment. Before re-designation of Ms. Li, Mr. Chan Lung Sang, a former executive director of the Company, was responsible for the overall operation and development of the Group's clinic segment until his retirement on 25 May 2018. Mr. Lau is currently the Group Financial Controller and company secretary of the Company.